M&A Deal Summary |
|
|---|---|
| Date | 2017-01-31 |
| Target | Akkadeas Pharma Srl |
| Sector | Life Science |
| Buyer(s) | Ipsen |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1929 |
| Sector | Life Science |
| Employees | 5,358 |
| Revenue | 3.6B EUR (2024) |
Ipsen is a research and development pharmaceutical company. It manufactures specialty pharmaceuticals and has a worldwide sales presence. Ipsen focuses on products in the gastro-enterology, neurology and cardiovascular therapeutic areas and has also developed specific expertise in some biotech niches such as endocrinology, oncology, neurology and hematology. Ipsen was founded in 1929 and is based in Boulogne-Billancourt, France.
| DEAL STATS | # |
|---|---|
| Overall | 7 of 12 |
| Sector: Life Science M&A | 7 of 12 |
| Type: Add-on Acquisition M&A Deals | 6 of 9 |
| Country: Italy M&A | 1 of 1 |
| Year: 2017 M&A | 2 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-01-08 |
Merrimack Pharmaceuticals - Oncology Assets
Cambridge, Massachusetts, United States Merrimack Pharmaceuticals, Inc. - Oncology Assets is a unique encapsulation formulation of irinotecan in a long-circulating liposomal form designed to increase the length of tumor exposure to irinotecan and its active metabolite SN-38. |
Buy | $575M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-02-13 |
Sanofi SA - Consumer Healthcare Products
Paris, France Sanofi SA - Consumer Healthcare Products includes Prontalgine®, an analgesic for the treatment of moderate to severe pain, which has grown at double digit rates over the last four years and is available only in France. The portfolio also includes Buscopan®2, an antispasmodic; Suppositoria Glycerini3, a laxative; and Mucothiol® and Mucodyne®4, expectorants for cough and flu. |
Buy | €83M |
